Tumor Necrosis Factor Inhibitor Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Tumor Necrosis Factor Inhibitor Drugs Market is segmented By Drug Type (Adalimumab (Humira), Certolizumab (Cimzia), Etanercept (Enbrel), Golimumab (Simponi), Infliximab (Remicade)), By Application (Crohn's Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Arthritis), By End-User (Hospital Pharmacies, Retail Pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

Global Tumor Necrosis Factor Inhibitor Drugs market is expected to grow at a CAGR Of 16.3 % during the forecast period 2024-2031.

TNF inhibitors, also called TNF blockers, biologic therapies, or anti-TNF drugs, help stop inflammation. They treat rheumatoid arthritis (RA), juvenile arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, Ulcerative Colitis (UC), and Crohn's disease.

Tumor Necrosis Factor Inhibitor Drugs Market Scope

For more insights Request Free Sample

Tumor Necrosis Factor Inhibitor Drugs Market Dynamics

The tumor necrosis factor inhibitor drug market growth is driven by rising incidences of various inflammatory conditions such as rheumatoid arthritis (RA), psoriasis, ankylosing spondylitis, ulcerative colitis (UC), Crohn's disease, and others.

The increasing prevalence of inflammatory conditions will drive market growth.

The tumor necrosis factor inhibitor drugs market growth is driven by rising incidences of various inflammatory conditions such as Rheumatoid Arthritis (RA), psoriasis, ankylosing spondylitis, Ulcerative Colitis (UC), Crohn's disease, and others. According to NIH, one of the major changes that occur during aging is the irregulated immune responses, leading to a chronic systemic inflammatory state. Therefore, the growing geriatric population is fueling the global market; for instance, Department of Economics and Social Affairs United States data shows that in 2020 the number of people aged 65 and over was around 272 million, which is predicted to reach 1.5 billion by 2050. Furthermore, according to the World Psoriasis Day consortium, around 125 million people worldwide, or 2 to 3 percent of the total population, have psoriasis; as per the University of Washington Medicine, 8% of the total healthy white Americans and 2-3% percent of the total healthy African Americans accounting for 300,000 Americans suffer ankylosing spondylitis. The Global RA Network reported that in 2021, over 350 million people with arthritis globally. In addition, according to NIH, in 2035, as compared to 2020, it is expected to show a 2.5 times increase in prevalence for Iran, accounting for 69 thousand cases, a 2.3 times growth for North Africa and the Middle East, totaling 220 thousand cases, quadrupling in the prevalence for India indicating 2.2 million cases, a 1.5 times rise for East Asia region reporting with 4.5 million, and high‐income Asia‐Pacific and Southeast Asia regions with 183 and 199 thousand cases respectively indicating a 1.6-fold elevation in prevalence.

Moreover, the research conducted by Crohn's & Colitis UK in 2022 indicates that 1 in every 123 people in the UK has either Crohn's disease or ulcerative colitis. Also, amounts to a total of nearly half a million people in the UK living with IBD. In addition, an increasing number of biosimilars entering the market is likely to increase the affordability and drive the consumption of TNF inhibitors, which in turn is projected to fuel the market globally during the forecast period.

The high cost of tumor necrosis factor inhibitor drugs and stringent regulatory framework will restrain the growth of the global tumor necrosis factor inhibitor drug market.

However, the high cost of tumor necrosis factor inhibitors drugs, stringent regulatory framework, and high-quality standards set by market leaders are some of the major factors hindering the market growth. For instance, according to NHS England, an interim reference price for the 40mg strength adalimumab is £3,550.00 per patient a year, including homecare costs.

Tumor Necrosis Factor Inhibitor Drugs Market Segmentation Analysis

The Adalimumab (Humira) is expected to grow at the fastest CAGR during the forecast period (2024-2031)

Adalimumab (Humira) held the largest market share in 2021 and is estimated to continue dominating the market throughout the forecast period (2022-2029). Owing to a large number of interventional clinical studies with Adalimumab. For instance, according to clinicaltrials.gov around 15 studies are active such as a comparative study between ABP 501 and Humira in participants with moderate to severe plaque psoriasis sponsered by Amgen and estimated to be completed by January 10, 2023, a study for changing the course of crohn's disease by an early use of Adalimumab (CURE) sponsered by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives and will be finished by March 2025, another long-term safety and efficacy study of Adalimumab in pediatric subjects with ulcerative colitis sponsered by AbbVie, predicted to compete on May 14, 2025, a study sponsered by Sinocelltech Ltd., with the pourpose to compare the efficacy and safety of SCT630 and Adalimumab (HUMIRA) in adults with plaque psoriasis and assumed to be finshed by December 31, 2022, and a phase 3 randomized, open label multicenter trial to investigate the efficacy of a treat-to-target (T2T) treatment strategy with Secukinumab (AIN457) as a first-line biologic compared to a standard-of-care (SOC) treatment over 36 weeks in patients with active axial spondyloarthritis (axSpA) sponsered by Novartis Pharmaceuticals.

Tumor Necrosis Factor Inhibitor Drugs Market Geographical Share

The North American region holds the largest market share of the global tumor necrosis factor inhibitor drugs market

North America commanded the global tumor necrosis factor inhibitor drugs market in 2021 and is estimated to hold the largest market size over the forecast period (2022-2029) owing to the rising incidence of inflammatory disorders such as rheumatoid arthritis (RA), psoriasis, ankylosing spondylitis, ulcerative colitis (UC), Crohn's disease, and others. The United States and Canada have the highest incidence and prevalence of inflammatory bowel disease (IBD) in North America. The Centers for Disease Control and Prevention informed that 1 out of 4 adults suffered arthritis in 2020 in the United States, and by 2040, over 78 million U.S. adults will have arthritis; according to the National Psoriasis Foundation studies, more than 8 million people in the U.S. had psoriasis in 2020. Hence, the demand for TNF drugs is highest in this region. Also, the presence of key manufacturers, proactive government initiatives and favorable reimbursement policies are driving the market in North America.

Tumor Necrosis Factor Inhibitor Drugs Companies and Competitive Landscape

Some of the major players in the tumor necrosis factor inhibitor drugs market are Amgen Inc, AbbVie Inc, Pfizer, Inc, Samsung Bioepis Co., Ltd., Sanofi, Novartis International AG, Johnson & Johnson Services, Merck & co., and others. The key players are adopting various key strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the tumor necrosis factor inhibitor drugs market globally. For instance, on July 27, 2021, AbbVie and Calico extended a collaboration focused on aging and age-related diseases. Also, in April 2021, Pfizer acquired Amplyx Pharmaceutical.

AbbVie Inc.

Overview:

AbbVie is a leading American biopharmaceutical company founded in 2013 as a spin-off from Abbott Laboratories. AbbVie is headquartered in Illinois, United States. AbbVie achieved global drug sales at $5 billion in 2020 and has a global presence in 170+ countries.

Product Portfolio:

AbbVie Inc’s product portfolio contains HUMIRA (Adalimumab).

The global tumor necrosis factor inhibitor drugs market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.